Development of a Novel HER2-Targeted Peptide Probe for Dual-Modal Imaging of Tumors
Journal of Medicinal Chemistry · 08.06.2023 · 66 (11) · 7523-7533
DOI: 10.1021/acs.jmedchem.3c00347 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 29.05.2023. Verfasst von Rui Cao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular Medicine, College of Life and Health Sciences, Northeastern University, Shenyang 110167, China. Hauptthemen laut MEDLINE: Gallium Radioisotopes, Positron-Emission Tomography. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Chinese Academy of Sciences.
Abstract (Originalsprache)
Human epidermal growth factor receptor 2 (HER2) may serve as a valid target for diagnosis of cancer. The probes with capability for near-infrared window one region II (NIR-II) and positron emission tomography (PET) dual-modal imaging are highly desired for HER2-positive tumor detection. Herein, three HER2-targeted peptides were designed and further modified with indocyanine green (ICG) and 2,2',2″,2″-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic acid (DOTA), which were used for NIR-II imaging and complexation with 68Ga for PET. Among the resulted probes (DOTA-ZC01-ICG, DOTA-KSP-ICG, and DOTA-ZC02-ICG), NIR-II imaging revealed that DOTA-ZC02-ICG had the best tumor imaging performance in SKOV3 tumor-bearing mice. The highest T/N ratio (5.4) was achieved at 4 h post-injection. Furthermore, DOTA-ZC02-ICG was radiolabeled with 68Ga to generate [68Ga]-DOTA-ZC02-ICG for PET, and it clearly delineated at 0.5, 1, and 2 h post-injection. The tumor uptake reached 1.9 %ID/g at 0.5 h, and the tumor uptakes were significantly inhibited in the blocking study (p < 0.05). Overall, it provides a promising technique for tumor dual-modal imaging and a new molecular scaffold for developing HER2-targeted theranostic agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Molecular Medicine, College of Life and Health Sciences, Northeastern University, Shenyang 110167, China.
- State Key Laboratory of Drug Research, Molecular Imaging Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
- Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong 264117, China.
ORCID-Profile: Rui Cao, Chaoquan Lai, Hongguang Liu, Zhen Cheng
Förderung
- National Natural Science Foundation of China
- Chinese Academy of Sciences
Zitieren
APA
Cao, R., Li, R., Lai, C., Shi, H., Liu, H., & Cheng, Z. (2023). Development of a Novel HER2-Targeted Peptide Probe for Dual-Modal Imaging of Tumors. Journal of Medicinal Chemistry, 66(11), 7523-7533. https://doi.org/10.1021/acs.jmedchem.3c00347
Vancouver
Cao R, Li R, Lai C, Shi H, Liu H, Cheng Z. Development of a Novel HER2-Targeted Peptide Probe for Dual-Modal Imaging of Tumors. Journal of Medicinal Chemistry. 2023;66(11):7523-7533. doi:10.1021/acs.jmedchem.3c00347
BibTeX
@article{Cao2023,
author = {Cao, Rui and Li, Renda and Lai, Chaoquan and Shi, Hui and Liu, Hongguang and Cheng, Zhen},
title = {Development of a Novel HER2-Targeted Peptide Probe for Dual-Modal Imaging of Tumors},
journal = {Journal of Medicinal Chemistry},
year = {2023},
volume = {66},
number = {11},
pages = {7523--7533},
doi = {10.1021/acs.jmedchem.3c00347}
}
EUVIMED